Damage limitation therapies that control the symptoms caused by a bug or virus in the body rather than killing it at the first place, may not be effective in the long term, scientists have found.
Damage limitation therapies focus on enabling the patient to tolerate disease and buy the immune system valuable time to get rid of the infection naturally.
Researchers at the Universities of Edinburgh and Liverpool in Britain created a mathematical model to look at how damage limitation drugs could affect how infections spread and evolve.
People given damage limitation therapies may appear healthy, but carry high levels of infection and so may be more likely to pass on disease, said the study published in the journal PLoS Biology.
"In treating infections with drugs, we change their environment, but bacteria and other infectious agents are incredibly good at adapting to their environment," said Pedro Vale of University of Edinburgh's school of biological sciences.
The researchers found that for certain infections, where the symptoms are not linked to the spread of disease, these drugs may prevent disease from evolving too quickly.
However, people with lesser symptoms could remain undiagnosed and add to the spread of disease, the study said.
"Damage limitation therapies may be a useful alternative to antibiotics, but we should be cautious, and investigate their potential long-term consequences," Vale added.
-Indo-Asian News Service
gb/na/rd
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
